Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

The real divide this earnings season is runway: who sets the timeline, and who is set by it

Revenue growth, settlements and trial milestones all matter, but the Q3 filings show the balance sheet decides who can act on them at a time of their own choosing.

16 Nov 2026 · CompePharma editorial

Same quarter, different freedoms

Read this batch of third-quarter results for what each company can do next, and the numbers sort into two groups. The first can choose its timing. The second has timing chosen for it.

Immunocore sits firmly in the first group. It reported $901 million in cash, cash equivalents and marketable securities at September 30. KIMMTRAK brought in $102.2 million in the quarter and $324.8 million over nine months, up 10% year to date. That is steady growth, not spectacular growth. The balance sheet is what lets Immunocore fund a Phase 3 melanoma trial that has completed enrollment of 540 patients, with overall survival topline expected in the second quarter of 2027. It can also plan a randomized Phase 2/3 in uveal melanoma and dose the first patient in a type 1 diabetes program. It can run all of this in parallel because no single readout has to rescue the company.

Talphera sits at the other end. It reported $14.2 million in cash and investments. Its news is substantive: the pivotal NEPHRO study exceeds 80% power for its primary endpoint, a briefing document is with FDA requesting an enrollment close based on patients enrolled as of December 31, and updated market research puts nafamostat peak sales in CRRT above $200 million. None of that is trivial. But a company with $14.2 million and a regulatory conversation still to resolve has little slack in its calendar. The commercial case is large relative to the cash, and the cash sets the pace.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →
Opinion · CompePharma View

A guidance raise is only as good as who controls the trigger

Q3 guidance moves look alike on a headline but differ in what they say about control. The companies that own their drivers have earned more trust than those waiting on a partner's calendar.

15 Nov 2026 · CompePharma editorial